CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Elicio Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Elicio Therapeutics Inc
One Kendall Square
Building 1400 West, Suite 14303
Phone: (857) 209-0056p:857 209-0056 CAMBRIDGE, MA  02139  United States
This company was Merged or Acquired on 6/1/2023.
This is a Subsidiary, click here for the Parent Company
Business Summary
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. It develops the Amphiphile (AMP) technology across immunotherapy platforms to defeat cancers and infectious diseases. The Company is engineering lymph node targeted cell therapy activators, immunomodulators, adjuvants and vaccines for an array of cancers and infectious diseases. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by KRAS, a mutation found in approximately 25% of tumors. Its pipeline also includes ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers, and ELI-004 an AMP-modified CpG adjuvant.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202112/31/2020YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Business Names
Business Name
Angion Biomedica Corp
Elicio Securities Corporation
Elicio Therapeutics Inc

General Information
Number of Employees: 22 (As of 3/31/2021)
Outstanding Shares: 13,878,314 (As of 7/13/2021)
Federal Tax Id: 452966790


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024